Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DYAI Stock Forecast 2026-2027
$1.22
Current Price
$44.46M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DYAI Price Targets
+473.8%
To High Target of $7.00
+391.8%
To Median Target of $6.00
+309.8%
To Low Target of $5.00
DYAI Price Momentum
+14.0%
1 Week Change
+56.4%
1 Month Change
+24.5%
1 Year Change
+29.8%
Year-to-Date Change
-9.6%
From 52W High of $1.35
+87.7%
From 52W Low of $0.65
📊 TOP ANALYST CALLS
Did DYAI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dyadic is one of their latest high-conviction picks.
Latest DYAI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, DYAI has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $7.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $1.22, the median forecast implies a 391.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DYAI Analyst Ratings
1
Buy
0
Hold
0
Sell
DYAI Price Target Range
Low
$5.00
Average
$6.00
High
$7.00
Current: $1.22
Latest DYAI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DYAI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 23, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $3.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 8, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 13, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 24, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 3, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 18, 2022 | Dawson James | Neutral | Downgrade | $N/A | |
| Apr 5, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 17, 2021 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Dyadic International Inc. (DYAI) Competitors
The following stocks are similar to Dyadic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dyadic International Inc. (DYAI) Financial Data
Dyadic International Inc. has a market capitalization of $44.46M with a P/E ratio of -5.2x. The company generates $3.81M in trailing twelve-month revenue with a -191.5% profit margin.
Revenue growth is +182.3% quarter-over-quarter, while maintaining an operating margin of -172.1% and return on equity of -2,826.9%.
Valuation Metrics
Market Cap
$44.46M
Enterprise Value
$36.61M
P/E Ratio
-5.2x
PEG Ratio
0.2x
Price/Sales
10.0x
Growth & Margins
Revenue Growth (YoY)
+182.3%
Gross Margin
-27.0%
Operating Margin
-172.1%
Net Margin
-191.5%
EPS Growth
+240.6%
Financial Health
Cash/Price Ratio
+12.6%
Current Ratio
2.4x
Debt/Equity
-12.4x
ROE
-2,826.9%
ROA
-56.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dyadic International Inc. (DYAI) Business Model
About Dyadic International Inc.
What They Do
Develops gene expression platforms for proteins.
Business Model
The company leverages its proprietary C1 technology to produce high-value proteins and industrial enzymes for non-pharmaceutical applications. By partnering with industry leaders like BASF and Codexis, Dyadic licenses its technology, generating revenue from these collaborations while helping clients streamline their production processes and reduce regulatory burdens.
Additional Information
Founded in 1979 and based in Jupiter, Florida, Dyadic International targets high-growth sectors such as life sciences, food and nutrition, and bioindustrial markets. Their focus on non-pharmaceutical products allows them to sidestep the complexities and costs associated with therapeutic biologics, positioning them as a valuable partner in bioprocessing and product development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Mark A. Emalfarb
Country
United States
IPO Year
2018
Website
www.dyadic.comDyadic International Inc. (DYAI) Latest News & Analysis
Latest News
Global Collaborations Continue to Validate Dyadic's C1 Platform and Expands Commercial Potential
9 days ago
Quick Summary
Dyadic's C1 platform gains validation through global collaborations, with ongoing Ebola preparedness efforts expanding its commercial opportunities.
Why It Matters
Dyadic's C1 platform's validation through global collaborations enhances its market potential, signaling growth opportunities and increased investor confidence in future revenues.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyadic International has received patent approval from the Japan Patent Office for its Thermothelomyces heterothallica recombinant protein expression technology, enhancing its biotechnology portfolio.
Why It Matters
The patent allowance boosts Dyadic's competitive edge, potentially leading to increased revenue from its scalable protein production technology across multiple sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Dyadic Applied BioSolutions (NASDAQ: DYAI) is advancing its growth strategy, focusing on commercialization in Life Sciences, Food & Nutrition, and Bio-industrial markets, including non-animal proteins.
Why It Matters
Dyadic's expansion into diverse markets and focus on strategic partnerships signals potential revenue growth, making it a key player in the evolving biotechnology sector.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Dyadic International (Nasdaq: DYAI) reports growing interest in its C1 protein production platform amid heightened global efforts to combat the Bundibugyo Ebola virus outbreak.
Why It Matters
Increased interest in Dyadic's C1 protein production platform amid Ebola concerns may boost demand and revenue, indicating potential growth and investment opportunities in biotechnology.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
1 month ago
Quick Summary
Dyadic International (NASDAQ: DYAI) is collaborating with Scripps Research to evaluate monoclonal antibodies and vaccines for hantaviruses, including Andes virus, linked to Hantavirus Pulmonary Syndrome.
Why It Matters
The collaboration between Dyadic and Scripps Research on hantavirus treatments could lead to significant advancements in biotechnology, potentially boosting Dyadic's market value and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The company is hosting a real-time interactive presentation for individual and institutional investors, advisors, and analysts at the Skyline Signature Series.
Why It Matters
The company's interactive presentation signals transparency and engagement, potentially boosting investor confidence and interest, impacting stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DYAI Stock
What is Dyadic International Inc.'s (DYAI) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Dyadic International Inc. (DYAI) has a median price target of $6.00. The highest price target is $7.00 and the lowest is $5.00.
Is DYAI stock a good investment in 2027?
According to current analyst ratings, DYAI has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DYAI stock?
Wall Street analysts predict DYAI stock could reach $6.00 in the next 12 months. This represents a 391.8% increase from the current price of $1.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dyadic International Inc.'s business model?
The company leverages its proprietary C1 technology to produce high-value proteins and industrial enzymes for non-pharmaceutical applications. By partnering with industry leaders like BASF and Codexis, Dyadic licenses its technology, generating revenue from these collaborations while helping clients streamline their production processes and reduce regulatory burdens.
What is the highest forecasted price for DYAI Dyadic International Inc.?
The highest price target for DYAI is $7.00 from at , which represents a 473.8% increase from the current price of $1.22.
What is the lowest forecasted price for DYAI Dyadic International Inc.?
The lowest price target for DYAI is $5.00 from at , which represents a 309.8% increase from the current price of $1.22.
What is the overall DYAI consensus from analysts for Dyadic International Inc.?
The overall analyst consensus for DYAI is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are DYAI stock price projections?
Stock price projections, including those for Dyadic International Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 10:04 AM UTC